CBG-002 / Carbiogene Therap - LARVOL DELTA

Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=38 | Not yet recruiting | Sponsor: Carbiogene Therapeutics Co. Ltd.

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

CD27-Armored BCMA CAR T Cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial. (PubMed, Cancer Immunol Res) - P1 | "The median OS was not reached, and the median PFS was 8.5 (2.7-22.9) months. In this phase I study, CBG-002, a CD27-armored BCMA CAR T therapy, demonstrated safety and clinical efficacy in patients with RRMM."

CAR T-Cell Therapy • Journal • P1 data • Hematological Disorders • Hematological Malignancies • Inflammation • Multiple Myeloma • Neutropenia • Oncology • Thrombocytopenia • CD27

Biomarkers to predict chemotherapy response in low-grade serous ovarian carcinoma (ESMO-GC 2024) - "Dr Seema Kumari was the recipient of a PhD Scholarship from Sydney Cancer Partners with funding from Cancer Institute NSW (2021/CBG0002)...We aimed to identify molecular features predictive of response to docetaxel, paclitaxel and gemcitabine in well-defined LGSC cell line models. Cell viability was assessed following docetaxel, paclitaxel and gemcitabine exposure in eight LGSC lines (CellTiter 96™ MTS Assay, Promega)... Our pre-clinical data suggests that non-platinum chemotherapy may be a viable option in selected LGSC patients. Gene expression profiles associated with response to specific agents were identified. However, these findings need further validation in patient samples."

Biomarker • Oncology • Ovarian Cancer • Ovarian Serous Adenocarcinoma • Solid Tumor

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - P1 | N=25 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Oct 2022 ➔ Oct 2023

CAR T-Cell Therapy • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - P1; N=25; Recruiting; Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University; Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma (clinicaltrials.gov) - P1; N=25; Not yet recruiting; Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

CAR T-Cell Therapy • New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology